Lipid-based Polyene Antifungal Drug Class List

Drugs in Drug Class: Lipid-based Polyene Antifungal

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avet Lifesciences	AMPHOTERICIN B	amphotericin b	INJECTABLE, LIPOSOMAL;INJECTION	215354-001	Jun 2, 2025	AB	RX	No	No
Xgen Pharms	AMPHOTERICIN B	amphotericin b	INJECTABLE;INJECTION	063206-001	Apr 29, 1992		RX	No	Yes
Eugia Pharma	AMPHOTERICIN B	amphotericin b	INJECTABLE, LIPOSOMAL;INJECTION	214010-001	Nov 17, 2022	AB	RX	No	No
Spil	AMPHOTERICIN B	amphotericin b	INJECTABLE, LIPOSOMAL;INJECTION	212514-001	Dec 14, 2021	AB	RX	No	No
Mylan Labs Ltd	AMPHOTERICIN B	amphotericin b	INJECTABLE, LIPOSOMAL;INJECTION	212967-001	Jun 30, 2025	AB	RX	No	No
Astellas	AMBISOME	amphotericin b	INJECTABLE, LIPOSOMAL;INJECTION	050740-001	Aug 11, 1997	AB	RX	Yes	Yes

Last updated: July 6, 2026

Market dynamics and patent landscape for lipid-based polyene antifungal drugs

Lipid-based polyene antifungals are a small, high-cost segment built around amphotericin B formulations. Patent estates cluster around (1) specific lipid carrier compositions, (2) manufacturing processes, and (3) methods of use for endemic mycoses and invasive fungal disease. Competitive pressure typically arrives via generic amphotericin B deoxycholate (lower cost) and, where approved, biosimilar-like entry is generally not applicable because these are small-molecule polyenes rather than biologics. The main exclusivity “risk surface” is the timing of last drug-substance and formulation patents plus any regulatory data exclusivity tied to specific listed products.

This page maps how the market works and how IP constrains generic or alternative-formulation competition across major lipid amphotericin brands in the class: AmBisome (liposomal amphotericin B) and other lipid-based amphotericin products that follow similar IP patterns in composition and process. It also outlines how Paragraph IV challenges generally form the entry pathway into FDA markets when patents are Orange Book-listed.

---

What lipid-based polyene antifungals are used most and why do they command premium pricing?

Featured answer: The lipid-based polyene antifungals are used for invasive fungal disease where clinicians want reduced nephrotoxicity relative to amphotericin B deoxycholate, accepting higher acquisition costs and logistics complexity.

Key market use cases (clinical and payer drivers)

Lipid-based polyene amphotericin B products are typically positioned for:

• Invasive aspergillosis and other invasive mould infections
• Cryptococcosis (especially in immunocompromised patients)
• Visceral leishmaniasis in select geographies and protocols
• Serious fungal infections in patients with renal impairment risk, where amphotericin B deoxycholate is constrained by toxicity

Market dynamics that shape demand

• Hospital formulary behavior: use is often restricted to ID/inpatient pathways, with prior authorization tied to severity or renal risk.
• Indications mix: access depends on local guideline alignment and the availability of competing agents (echinocandins, azoles, combination regimens).
• Supply chain and cost: lipid formulations require specific manufacturing and cold/handling systems depending on presentation, which affects procurement cadence and substitution decisions.

Commercial structure

• High share of spend is concentrated among a small number of oncology, transplant, and ICU-heavy hospital networks.
• Tendering can force price compression, but IP still determines whether true substitution is allowed.

---

Which patents protect lipid-based polyene antifungals like AmBisome (liposomal amphotericin B)?

Featured answer: Patent protection is dominated by claims on lipid composition, liposome particle characteristics, drug-to-lipid ratios, encapsulation method, and manufacturing steps that control size, lamellarity, and stability. Process patents and formulation patents often extend beyond the initial compound filing through incremental improvements.

Typical IP buckets in the lipid amphotericin B space

Across lipid-based polyenes, patent families cluster into:

1. Lipid carrier composition patents

   • Specific phospholipid mixtures
   • Cholesterol or other membrane stabilizers
   • Optional charge modifiers and surface-active components

2. Encapsulation and drug loading patents

   • Amphotericin B-to-lipid ratios
   • Techniques that control association and encapsulation efficiency
   • Control of aggregation state that drives tolerability

3. Manufacturing process patents

   • Thin-film hydration, solvent evaporation variants, lipid film formation conditions
   • Particle size reduction steps (e.g., extrusion or sonication)
   • Lyophilization or sterile filtration process details that affect shelf life

4. Stability and particle specification patents

   • Shelf-life stability targets
   • Particle size distribution limits
   • Prevention of amphotericin B aggregation during storage

5. Methods of use

   • Specific dosing regimens, patient populations, and combination therapies

How these patents matter for competitive entry

Because the carrier composition and particle properties drive clinical outcomes (toxicity profile), generic “label-equivalent” products still risk infringement if their internal formulation and process do not land inside non-infringing boundaries.

---

What is the Orange Book status of liposomal amphotericin B and other lipid-based polyene antifungals?

Featured answer: FDA Orange Book listings for lipid amphotericin products generally include patents tied to drug substance and drug product plus exclusivity flags where applicable. Entry timing depends on the last listed patent expiration and whether any exclusivity periods remain.

Orange Book-driven risks

• If key patents are listed for the specific dosage form and strength, ANDA applicants face formulation and process infringement risk.
• If multiple patents expire at different times, the Orange Book “last-to-expire” date is the main gating item for market entry.

Practical read-through for diligence

• Track patent numbers, expiration dates, and claims scope for:
  • “Drug Substance”
  • “Drug Product”
  • “Method of Use”
• Confirm whether patents cover “same drug” under generic labeling, or whether formulation-specific patents block AB-equivalence substitutes.

(No product-specific patent list can be accurately reproduced here because the underlying Orange Book dataset is not provided in the prompt.)

---

When does exclusivity and patent protection end for lipid-based polyene antifungals?

Featured answer: Exclusivity typically ends before or around the expiration of the last Orange Book-listed formulation and process patents; entry timing is controlled by “last relevant patent” rather than by marketing authorization date alone.

Exclusivity timeline drivers

Patent and regulatory exclusivity typically run in parallel:

• Drug-product patents and formulation/process patents: often the last to expire because they protect the specific lipid system.
• Method-of-use patents: may remain even after product formulation patents expire, depending on claim coverage.

Generic entry sequencing

1. ANDA filing with Paragraph IV certifications to the relevant patents
2. Potential 30-month stay triggered by litigation
3. Settlement can create design-around and launch-date commitments
4. Launch depends on:
   • last expiration date
   • design freedom from composition/process claims
   • whether additional patents are asserted later

---

Which Paragraph IV challenges are used for lipid-based polyene antifungals, and what do they target?

Featured answer: When challengers seek early entry, they usually target formulation/process patents, arguing non-infringement or invalidity for specific lipid composition and manufacturing steps.

Common Paragraph IV target patterns

• Composition claims: challengers argue their lipid ratios, cholesterol content, or minor components differ.
• Process claims: challengers argue different manufacturing steps or controls yield a non-infringing product.
• Particle specification claims: challengers rely on measured differences in size distribution or stability.

Litigation outcomes that move the market

• Narrow claim construction can preserve key product lines for brand owners.
• Broad composition claims can force redesign or settlement.
• Invalidity wins are less common than infringement disputes because formulation characterization can be technically complex.

---

How does AmBisome compare with alternative amphotericin B formulations for toxicity, dosing, and substitution risk?

Featured answer: Liposomal amphotericin B is generally preferred for reduced nephrotoxicity, and substitution risk is higher than simple chemical equivalence suggests because the lipid-carrier system drives tolerability and exposure kinetics.

Substitution dynamics

• Amphotericin B deoxycholate is chemically the same amphotericin B active but differs in formulation and clinical management.
• Payers may allow deoxycholate use in low-risk patients, but hospitals often preserve liposomal amphotericin in high-risk renal scenarios.
• Formularies can restrict substitution based on:
  • creatinine clearance cutoffs
  • ICU or immunocompromised protocols
  • guideline adherence

IP implications

Even if dosing regimens overlap, formulation differences create infringement risk for any “generic lipid” attempt that does not materially deviate from protected composition/process structures.

---

What formulations are protected in lipid-based polyene antifungal patent estates (liposome size, lipid ratios, and manufacturing steps)?

Featured answer: The most enforceable claim sets usually tie together lipid ratios, liposome particle characteristics, and the manufacturing process that controls those characteristics.

Formulation elements that commonly appear in claim scope

• Phospholipid identity and ratio (neutral vs charged components)
• Cholesterol or similar membrane stabilizers
• Drug-to-lipid loading ratio targets
• Particle size and distribution windows
• Encapsulation efficiency and association state
• Methods of preparing liposomes and controlling aggregation during manufacture and storage
• Final product presentation, including lyophilized vs aqueous formats and reconstitution parameters

Design-around pressure points

A competitor seeking non-infringement typically must change one of:

• lipid composition sufficiently to avoid literal or doctrine-of-equivalents coverage
• manufacturing controls and steps such that particle specifications fall outside claim limits
• stability mechanisms so the resulting product does not meet the claimed specification targets

---

What method-of-use patents exist for lipid-based polyene antifungals, and when do they affect generic entry?

Featured answer: Method-of-use patents can extend brand leverage after formulation patents expire, but they usually affect entry only if the generic product’s label is constrained or if physicians are targeted in enforcement.

How method-of-use patents create leverage

• If the brand’s labeled regimen remains covered by method patents, generics still can sell the product but may face restrictions depending on infringement theories and jurisdiction.
• Brand owners can assert method-of-use claims in jurisdictions that support inducement or active inducement theories.

Where method patents matter most

• High-value indications with entrenched prescribing patterns:
  • invasive aspergillosis protocols
  • endemic mycoses regimens
  • special populations such as renal impairment or pediatric use

---

Which companies are challenging lipid-based polyene antifungals and what settlement patterns appear?

Featured answer: Patent challenges tend to come from ANDA applicants positioned as lower-cost entrants, with settlement often structured around delayed launch dates, licensing terms for a narrower footprint, or partial carve-outs based on dosage forms.

Settlement structures seen in this category

• Launch-date settlements that avoid design-work and litigation risk
• Royalty-bearing licenses if the ANDA is granted but brand asserts remaining patents
• Consent decrees or stipulations that define which patents remain litigable

Commercial relevance

• Even when a product is on track for ANDA approval, the last-to-expire patent and the settlement “delay” govern whether a competitor can monetize volume quickly.

(Company and case identifiers are not listed here because the prompt does not include a target brand list, FDA product identifiers, or Orange Book case data.)

---

What patent litigation affects lipid-based polyene antifungals, including 30-month ANDA stays?

Featured answer: Litigation is the primary mechanism that delays generic entry after Paragraph IV filings through the automatic 30-month stay, unless the case is resolved earlier or the applicant faces adverse court rulings.

Timeline mechanics

• Paragraph IV notice triggers litigation in federal court.
• Courts can decide:
  • infringement
  • validity
  • injunction scope
• The 30-month stay is lifted if the decision timeline shortens.

IP strategy implications for R&D

• Brands: assert multiple patents with strongest infringement records, including formulation and process.
• Challengers: select a smaller set of patents for validity attack and focus on non-infringement at characterization level.

---

What is the biosimilar risk for lipid-based polyene antifungals?

Featured answer: Biosimilar frameworks do not apply because lipid-based polyene antifungals are not biologics; the competitive threat is from generics via ANDAs rather than biosimilars via BLA pathways.

Competitive analog

• “Generic liposomal amphotericin” is still an ANDA-type problem even if colloquial “biosimilar-like” language appears in market commentary.

---

How do manufacturing and IP barriers work for generic lipid-based polyene antifungals?

Featured answer: Even after legal allowance, manufacturing feasibility and product characterization are critical because formulation and particle properties are tightly linked to efficacy and tolerability.

Barrier categories

• Process know-how: lipid film formation and particle size controls are not trivial scale-up items.
• Analytical characterization: particle size distribution, encapsulation state, and stability require robust testing.
• Batch variability: minor composition and manufacturing differences can move the product out of a claimed specification or alter clinical equivalence.

Resulting market effect

• Legal entry does not always translate into rapid volume capture; time to scale and ensure consistent quality delays uptake.

---

Which generic entry risks exist for lipid-based polyene antifungals if key patents expire?

Featured answer: If the last Orange Book-listed formulation and process patents expire, generic entry risk rises sharply, but lingering method-of-use patents or stability-specific patents can still limit non-infringing alternatives.

Launch readiness checklist used in patent diligence

• Last-to-expire drug product and drug substance patents
• Any method-of-use patents tied to labeled regimens
• Whether additional patents are expected to be listed later through patent-addition pathways
• Whether litigation is ongoing against the competitor’s product approach

---

How does the patent estate for lipid-based polyene antifungals compare with other invasive antifungals like echinocandins and triazoles?

Featured answer: Lipid polyenes have fewer active players but heavier formulation/process patent gravity; echinocandins and triazoles face broader chemical space innovation with different patent structures (chemical entity, salts, polymorphs, and method-of-use), often with more generics than lipid polyenes at similar lifecycle stages.

Why lipid polyenes behave differently

• The therapeutic differentiator is formulation-controlled toxicity and tolerability.
• That makes carrier composition and process patents central, not peripheral.

---

Key Takeaways

• Lipid-based polyene antifungals are priced and positioned on tolerability advantages driven by lipid carrier formulation.
• Patent protection is dominated by lipid composition, drug loading, particle characteristics, and manufacturing process controls, which create high infringement sensitivity for “generic lipid” entrants.
• Generic entry risk is driven by last-to-expire Orange Book-listed formulation and process patents and the presence of method-of-use patents.
• Biosimilar pathways are not relevant; competitive threats are ANDA-based and shaped by litigation-driven 30-month stays and settlement structures.
• Even when patents expire or litigation ends, manufacturing know-how and analytical comparability can delay commercial uptake.

---

FAQs

1. Do lipid-based polyene antifungals have device or delivery-system patents that block substitution?
2. Can a generic amphotericin B lipid product be designed to avoid infringement by changing particle size distribution only?
3. What patent categories typically remain enforceable after drug-substance patent expiry for liposomal amphotericin B?
4. How do FDA labeling updates (strength, dosage form, reconstitution instructions) affect Orange Book patent relevance?
5. What is the typical effect of a settlement on launch timing for ANDA challengers in lipid amphotericin B cases?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Patent and Exclusivity for Drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/patent-and-exclusivity-drugs